AcuCort is a biotechnology company. The company has developed and commercializes the drug Zeqmelit, which is an oral film based on the cortisone substance dexamethasone, for quick availability and relief in, for instance, severe and acute allergic reactions. Zeqmelit is approved in Sweden, Denmark and Norway. The goal is global commercialization in the EU, USA and in selected key markets via licensees and distributors. The company has its headquarters in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Aqilion AB | 16,20 | 16,20 | 2023-09-27 |
| Avanza Pension | 8,80 | 8,80 | 2023-09-27 |
| Erik Fällström via bolag | 7,34 | 7,34 | 2023-09-27 |
| Zoya Invest AB | 5,75 | 5,75 | 2023-09-27 |
| Berne Gilbert Okdah | 2,83 | 2,83 | 2023-09-27 |
| Nordnet Pensionsförsäkring | 2,09 | 2,09 | 2023-09-27 |
| Sparbanksstiftelser – Ej Sparbanksgruppen | 1,60 | 1,60 | 2023-09-27 |
| Alexander Svensson | 1,60 | 1,60 | 2023-09-27 |
| Göran Ofsén | 1,60 | 1,60 | 2023-09-27 |
| Carin Lindeberg | 1,28 | 1,28 | 2023-09-27 |